0000000000765867

AUTHOR

Sebastian Bröckling

showing 2 related works from this author

Blood group antigen A type 3 expression is a favorable prognostic factor in advanced NSCLC.

2015

Abstract Objectives Several blood group-related carbohydrate antigens are prognosis-relevant markers of tumor tissues. A type 3 (repetitive A) is a blood group antigen specific for A 1 erythrocytes. Its potential expression in tumor tissues has so far not been examined. Material and methods We have evaluated its expression in normal lung and in lung cancer using a novel antibody (A69-A/E8). For comparison an anti-A antibody specific to A types 1 and 2 was used, because its expression on lung cancer tissue has been previously reported to be of prognostic relevance. Resected tissue samples of 398 NSCLC patients were analyzed in immunohistochemistry using tissue microarrays. Results and conclu…

0301 basic medicinePulmonary and Respiratory MedicineOncologyMaleCancer Researchmedicine.medical_specialtyPathologyLung Neoplasms03 medical and health sciences0302 clinical medicineAntigenAntigens NeoplasmInternal medicineCarcinoma Non-Small-Cell LungmedicineBiomarkers TumorHumansLung cancerProspective cohort studyAgedTissue microarrayLungbiologyProportional hazards modelbusiness.industrymedicine.diseasePrognosisImmunohistochemistrySurvival Analysisrespiratory tract diseases030104 developmental biologymedicine.anatomical_structureOncologyTissue Array Analysis030220 oncology & carcinogenesisbiology.proteinBlood Group AntigensImmunohistochemistryFemaleAntibodybusinessLung cancer (Amsterdam, Netherlands)
researchProduct

The prognostic impact of PD1 and PDL1 expression in non-small cell lung cancer

2015

Introduction: To improve the prognosis of lung cancer patients, immunotherapy is expected to become a powerful therapeutic option. Several clinical studies demonstrate a positive prognostic effect of a targeted therapy against the programmed cell death receptor PD1 and its ligand PDL1 in solid tumors. For non-small lung cancer (NSCLC) however, the diagnostic, prognostic and predictive impact of these factors needs to be clarified. Materials and Methods: Immunohistochemistry was performed to evaluate the expression profile of PD1 and PDL1 in 398 NSCLC patients (median age: 66 years, 78% male sex, 45% squamous cell carcinoma (SCC) histology). Statistical analysis included Fisher9s Exact test,…

Oncologymedicine.medical_specialtyPathologybusiness.industryTumor-infiltrating lymphocytesmedicine.medical_treatmentContext (language use)Immunotherapymedicine.diseaseTargeted therapyLog-rank testExact testInternal medicinemedicineAdjuvant therapybusinessLung cancer11.1 Lung Cancer
researchProduct